生体電気医学の世界市場：2025年～2033年

世界の生物電気医学の市場規模は、2024年に313億4,000万米ドルに達し、2033年には2,355億5,000万米ドルに達すると予測され、予測期間の2025年～2033年のCAGRは22.3%となる見込みです。

電気製剤としても知られる生体電気医学は、不整脈、てんかん、パーキンソン病、慢性疼痛などの病気を治療するために電気インパルスを使用する医学です。特定の神経や組織を刺激する植え込み型デバイスを使用し、神経学、心臓病学、その他の治療分野において、医薬品に代わる革新的な治療法を提供します。この技術は神経調節と生体工学を統合し、患者の転帰を向上させます。

生体電気医療市場は、心血管障害、神経疾患、慢性疼痛などの慢性疾患の有病率の上昇、人口の高齢化、不整脈、てんかん、パーキンソン病の症例の増加によって牽引され、神経調節技術の進歩や電気治療アプリケーションの拡大がその原動力となっています。例えば、国際糖尿病連合（The International Diabetes Federation）の報告によると、2021年には成人の10人に1人にあたる5億3,660万人が糖尿病を患っており、その数は2030年には6億4,280万人、2045年には7億8,370万人に増加すると予測されており、特に低・中所得国において糖尿病治療薬と機器の緊急の必要性が浮き彫りになっています。

したがって、糖尿病有病率の増加は、生体電気医療を含む高度な治療ソリューションの需要を促進しています。神経調節装置のような生体電気療法は、特に低・中所得国において、合併症を管理し患者の転帰を改善するための有望な選択肢を提供します。

生体電気医療市場は、感染症、誤作動、免疫反応などの潜在的な機器関連合併症による課題に直面しています。植え込み型生体電気装置は外科的処置を必要とするため、術後の感染症、電極のずれ、ハードウェアの故障のリスクがあります。長期間の使用はデバイスの交換を必要とし、ヘルスケアコストと患者の不安を増大させ、バイオエレクトリック医療の普及を制限する可能性があります。

当レポートでは、世界の生体電気医学市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界見通し

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 製品タイプ別

• 埋め込み型デバイス
• 非侵襲性デバイス

第6章 用途別

• 不整脈
• 感音難聴
• てんかん
• パーキンソン病
• その他

第7章 エンドユーザー別

• 病院
• 外来手術センター
• その他

第8章 地域別市場分析と成長機会

• 北米
  • 地域特有の主要な動向
    • 米国
    • カナダ
    • メキシコ
• 欧州
  • 地域特有の主要な動向
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他
• ラテンアメリカ
  • 地域特有の主要な動向
    • ブラジル
    • アルゼンチン
    • その他
• アジア太平洋
  • 地域特有の主要な動向
    • 中国
    • インド
    • 日本
    • 韓国
    • その他
• 中東・アフリカ
  • 地域特有の主要な動向

第9章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第10章 企業プロファイル

• Medtronic Plc
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Abbott Laboratories
• Boston Scientific Corporation
• LivaNova PLC
• Biotronik SE &Co. KG
• Nevro Corp.
• Cochlear Ltd.
• electroCore, Inc.
• Axonics, Inc.
• NeuroPace, Inc.

第11章 仮定と調査手法

第12章 付録

The global bioelectric medicine market reached US$ 31.34 billion in 2024 and is expected to reach US$ 235.55 billion by 2033, growing at a CAGR of 22.3% during the forecast period 2025-2033.

Bioelectric medicine, also known as electroceuticals, is a medical science that uses electrical impulses to treat diseases like arrhythmia, epilepsy, Parkinson's, and chronic pain. It involves implantable devices that stimulate specific nerves or tissues, offering innovative alternatives to pharmaceutical treatments in neurology, cardiology, and other therapeutic areas. This technology integrates neuromodulation and bioengineering, enhancing patient outcomes.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Chronic Diseases

The bioelectric medicine market is driven by the increasing prevalence of chronic diseases like cardiovascular disorders, neurological conditions, and chronic pain, as well as the aging population and increasing cases of arrhythmia, epilepsy, and Parkinson's disease, driven by advancements in neuromodulation technology and expanding electroceutical applications. For instance, The International Diabetes Federation reports that in 2021, 536.6 million adults, or 1 in 10 people, were living with diabetes, with the number predicted to rise to 642.8 million by 2030 and 783.7 million by 2045, particularly in low- and middle-income countries, highlighting the urgent need for diabetes care drugs and devices.

Hence, the increasing diabetes prevalence is driving demand for advanced treatment solutions, including bioelectric medicine. Bioelectric therapies, like neuromodulation devices, offer promising alternatives for managing complications and improving patient outcomes, especially in low- and middle-income countries.

Risk of Device-Related Complications

The bioelectric medicine market faces challenges due to potential device-related complications like infections, malfunctions, and immune responses. Implantable bioelectric devices require surgical procedures, posing risks of post-operative infections, electrode displacement, and hardware failure. Long-term use may require device replacements, increasing healthcare costs and patient concerns, potentially limiting bioelectric medicine's widespread adoption.

Segment Analysis

The global bioelectric medicine market is segmented based on product type, application, end-user and region.

Product Type:

The implantable devices from the product type segment are expected to dominate the bioelectric medicine market with the highest market share

Implantable devices are medical instruments that are surgically placed inside the body to deliver targeted electrical stimulation for therapeutic purposes. They, including pacemakers, ICDs, deep brain stimulators, spinal cord stimulators, and vagus nerve stimulators, work by modulating neural or muscular activity to restore normal physiological functions. They are widely used in treating cardiovascular, neurological, and chronic pain conditions, offering long-term solutions with minimal reliance on pharmaceuticals.

The implantable devices segment is driven by the rise in chronic diseases, particularly cardiovascular and neurological disorders. Technological advancements like miniaturization, wireless connectivity, and rechargeable battery systems are enhancing device efficiency and patient convenience. Growing geriatric populations, expanding healthcare infrastructure, and increased awareness about neuromodulation therapies further boost market growth. Favorable reimbursement policies and research investments contribute to this growth.

For instance, in October 2024, a Carnegie Mellon University-led team was awarded up to $42 billion by ARPA-H to develop implantable, cell-based bioelectric devices for real-time disease monitoring and patient-specific therapy. This is part of the ARPA-H REACT program, which aims to improve chronic disease management through implantable bioelectronic devices.

Geographical Analysis

North America is expected to hold a significant position in the bioelectric medicine market with the highest market share

North America leads the global bioelectric medicine market due to product launches, advanced healthcare infrastructure, innovative medical technologies, and key market players. The region's high prevalence of chronic diseases, favorable reimbursement policies, and investments in neuromodulation research drive demand for implantable bioelectric devices like pacemakers and neurostimulators. Additionally, rising healthcare expenditure and growing awareness of electroceutical therapies contribute to the expanding use of bioelectric medicine in North America.

For instance, in June 2024, electroCore, Inc., a bioelectronic medicine and wellness company, announced the Commercial Off the Shelf (COTS) availability of the next generation TAC-STIM, a non-invasive vagus nerve stimulator designed in partnership with the US military for active-duty military use.

Competitive Landscape

The major global players in the bioelectric medicine market include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, Biotronik SE & Co. KG, Nevro Corp., Cochlear Ltd, electroCore, Inc., Axonics, Inc., and NeuroPace, Inc., among others.

Key Developments

• In July 2023, Boston Scientific Corporation received FDA approval for its Vercise Neural Navigator 5 software, which is designed to be used alongside Vercise Genus deep brain stimulation systems. This software offers clinicians practical data for treating Parkinson's disease or essential tremor, allowing them to efficiently program the DBS system.

Why Purchase the Report?

• Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global bioelectric medicine market report delivers a detailed analysis with 62 key tables, more than 53 visually impactful figures and 165 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product Type
• 2.4. Snippet by Application
• 2.5. Snippet by End-User
• 2.6. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Increasing Prevalence of Chronic Diseases
    • 3.1.1.2. Rise in Technological Advancements
  • 3.1.2. Restraints
    • 3.1.2.1. Risk of Device-Related Complications
    • 3.1.2.2. Stringent Regulatory Requirements and Approval Delays
  • 3.1.3. Opportunity
    • 3.1.3.1. Rise in Investment in Research and Development
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. Latin America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Force Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. By Product Type

• 5.1. Introduction
  • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 5.1.2. Market Attractiveness Index, By Product Type
• 5.2. Implantable Devices*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Pacemakers
  • 5.2.4. ICDs
  • 5.2.5. Cochlear Implants
  • 5.2.6. Spinal Cord Stimulators
  • 5.2.7. Deep Brain Stimulators
  • 5.2.8. Vagus Nerve Stimulators
  • 5.2.9. Sacral Nerve Stimulatord
• 5.3. Non-Invasive Devices

6. By Application

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 6.1.2. Market Attractiveness Index, By Application
• 6.2. Arrhythmia*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Sensorineural Hearing Loss
• 6.4. Epilepsy
• 6.5. Parkinson's Disease
• 6.6. Others

7. By End-User

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 7.1.2. Market Attractiveness Index, By End-User
• 7.2. Hospitals*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Ambulatory Surgical Centers
• 7.4. Others

8. Regional Market Analysis and Growth Opportunities

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.6.1. U.S.
    • 8.2.6.2. Canada
    • 8.2.6.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.6.1. Germany
    • 8.3.6.2. U.K.
    • 8.3.6.3. France
    • 8.3.6.4. Spain
    • 8.3.6.5. Italy
    • 8.3.6.6. Rest of Europe
• 8.4. Latin America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.6.1. Brazil
    • 8.4.6.2. Argentina
    • 8.4.6.3. Rest of Latin America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.6.1. China
    • 8.5.6.2. India
    • 8.5.6.3. Japan
    • 8.5.6.4. South Korea
    • 8.5.6.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

• 9.1. Competitive Overview and Key Market Players
• 9.2. Market Share Analysis and Positioning Matrix
• 9.3. Strategic Partnerships, Mergers & Acquisitions
• 9.4. Key Developments in Product Portfolios and Innovations
• 9.5. Company Benchmarking

10. Company Profiles

• 10.1. Medtronic Plc*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals, etc.
  • 10.1.5. SWOT Analysis
• 10.2. Abbott Laboratories
• 10.3. Boston Scientific Corporation
• 10.4. LivaNova PLC
• 10.5. Biotronik SE & Co. KG
• 10.6. Nevro Corp.
• 10.7. Cochlear Ltd.
• 10.8. electroCore, Inc.
• 10.9. Axonics, Inc.
• 10.10. NeuroPace, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

• 11.1. Data Collection Methods
• 11.2. Data Triangulation
• 11.3. Forecasting Techniques
• 11.4. Data Verification and Validation

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us